Last reviewed · How we verify
chloroquine, sulphadoxine pyrimethamine, LLIN
chloroquine, sulphadoxine pyrimethamine, LLIN is a Antimalarial Small molecule drug developed by University of Melbourne. It is currently in Phase 3 development for Malaria prevention and treatment. Also known as: sulfadoxine-pyrimethamine.
Chloroquine works by inhibiting the growth of the malaria parasite in the red blood cells, while sulphadoxine pyrimethamine acts as a folate antagonist, disrupting the parasite's metabolism.
Chloroquine works by inhibiting the growth of the malaria parasite in the red blood cells, while sulphadoxine pyrimethamine acts as a folate antagonist, disrupting the parasite's metabolism. Used for Malaria prevention and treatment.
At a glance
| Generic name | chloroquine, sulphadoxine pyrimethamine, LLIN |
|---|---|
| Also known as | sulfadoxine-pyrimethamine |
| Sponsor | University of Melbourne |
| Drug class | Antimalarial |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
Chloroquine is a 4-aminoquinoline that accumulates in the acidic compartments of the malaria parasite, disrupting its digestive vacuole and ultimately leading to the parasite's death. Sulphadoxine pyrimethamine, on the other hand, inhibits dihydropteroate synthase, an enzyme crucial for the synthesis of folic acid in the parasite, thereby disrupting its metabolism and preventing it from replicating.
Approved indications
- Malaria prevention and treatment
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Headache
- Dizziness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- chloroquine, sulphadoxine pyrimethamine, LLIN CI brief — competitive landscape report
- chloroquine, sulphadoxine pyrimethamine, LLIN updates RSS · CI watch RSS
- University of Melbourne portfolio CI
Frequently asked questions about chloroquine, sulphadoxine pyrimethamine, LLIN
What is chloroquine, sulphadoxine pyrimethamine, LLIN?
How does chloroquine, sulphadoxine pyrimethamine, LLIN work?
What is chloroquine, sulphadoxine pyrimethamine, LLIN used for?
Who makes chloroquine, sulphadoxine pyrimethamine, LLIN?
Is chloroquine, sulphadoxine pyrimethamine, LLIN also known as anything else?
What drug class is chloroquine, sulphadoxine pyrimethamine, LLIN in?
What development phase is chloroquine, sulphadoxine pyrimethamine, LLIN in?
What are the side effects of chloroquine, sulphadoxine pyrimethamine, LLIN?
Related
- Drug class: All Antimalarial drugs
- Manufacturer: University of Melbourne — full pipeline
- Therapeutic area: All drugs in Infectious Diseases
- Indication: Drugs for Malaria prevention and treatment
- Also known as: sulfadoxine-pyrimethamine
- Compare: chloroquine, sulphadoxine pyrimethamine, LLIN vs similar drugs
- Pricing: chloroquine, sulphadoxine pyrimethamine, LLIN cost, discount & access